https://orcid.org/0000-0002-6585-7406
References
- Anderson, K. M. (2019), “gsDesign: An R Package for Designing Group Sequential Clinical Trials Version 2.4 manual.”
- Berry, D. A., and Hudis, C. A. (2015), “Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval,” JAMA Oncology, 1, 875–876. DOI: 10.1001/jamaoncol.2015.1293.
- FDA. (2020a), “FDA Peripheral and Central Nervous System Drugs ACM Sponsor Slides,” https://www.fda.gov/media/143577/download
- FDA. (2020b), “Final Summary Minutes of the Peripheral and Central Nervous System Drugs ACM November 6, 2020,” https://www.fda.gov/media/145690/download
- FDA. (2020c), “FDA Briefing Document Vaccines and Related Biological Products ACM,” https://www.fda.gov/media/144246/download
- FDA. (2020d), “FDA Final Summary Minutes of Vaccines and Related Biological Products ACM December 10, 2020,” https://www.fda.gov/media/144958/download
- FDA. (2020e), “FDA Briefing Document Cardiovascular and Renal Drugs ACM,” https://www.fda.gov/media/144377/download
- FDA. (2020f), “FDA CDER Final Summary Minutes of the Cardiovascular and Renal Drugs ACM December 15, 2020,” https://www.fda.gov/media/145549/download
- FDA. (2021a), “Combined FDA and MSD Briefing Document for the February 9, 2021 Meeting of the Oncologic Drugs Advisory Committee,” https://www.fda.gov/media/145654/download
- FDA. (2021b), “FDA Final Materials of the February 9, 2021 Meeting of the Oncologic Drugs Advisory Committee,” https://www.fda.gov/media/145771/download
- Jennison, C., and Turnbull, B. (2000), Group Sequential Methods with Applications to Clinical Trials, Boca Raton: Chapman and Hall.
- Müller, H.-H., and Schäfer, H. (2001), “Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches,” Biometrics, 57, 886–891. DOI: 10.1111/j.0006-341x.2001.00886.x.
- Pivot, X., Schneeweiss, A., Verma, S., Thomssen, C., Passos-Coelho, J. L., Benedetti, G., Ciruelos, E., von Moos, R., Chang, H.-T., Duenne, A.-A. et al. (2011), “Efficacy and Safety of Bevacizumab in Combination with Docetaxel for the First-Line Treatment of Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: Results from AVADO,” European Journal of Cancer, 47, 2387–2395. DOI: 10.1016/j.ejca.2011.06.018.
- Proschan, M. A., Lan, K. G., and Wittes, J. T. (2006), Statistical Monitoring of Clinical Trials: A Unified Approach, New York: Springer.
- Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A., Bondarenko, I., Lipatov, O., Perez, E., Yardley, D., Zhou, X., and Phan, S. (2009), “RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or Without Bevacizumab for First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC),” Journal of Clinical Oncology, 27, 1005–1005. DOI: 10.1200/jco.2009.27.15_suppl.1005.
- Sasich, L. D., and Sukkari, S. R. (2012), “The US FDAs Withdrawal of the Breast Cancer Indication for Avastin (bevacizumab),” Saudi Pharmaceutical Journal, 20, 381–385. DOI: 10.1016/j.jsps.2011.12.001.
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020), “Pembrolizumab for Early Triple-Negative Breast Cancer,” New England Journal of Medicine, 382, 810–821. DOI: 10.1056/NEJMoa1910549.